2023 SABCS Highlights

CE / CME

Highlights From the 2023 San Antonio Breast Cancer Symposium

Physician Assistants/Physician Associates: 1.25 AAPA Category 1 CME credits

Nurses: 1.25 Nursing contact hours

Physicians: maximum of 1.25 AMA PRA Category 1 Credits

Pharmacists: 1.25 contact hours (0.125 CEUs)

Released: February 23, 2024

Expiration: February 22, 2025

Sara A. Hurvitz
Sara A. Hurvitz, MD, FACP
Joyce O'Shaughnessy
Joyce O'Shaughnessy, MD

Activity

Progress
1 2
Course Completed

Introduction

In this module, Sara A. Hurvitz, MD, and Joyce O’Shaughnessy, MD, discuss key studies in breast cancer presented at the 2023 San Antonio Breast Cancer Symposium (SABCS), with a focus on the clinical implications of new data.

Please note that the slide thumbnails in this activity link to PowerPoint slidesets, each focused on the specific study or topic of interest. These slidesets may be downloaded by clicking on any of the thumbnails within the activity.

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity and once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare professional, how many patients with breast cancer do you provide care for in a typical month?

Based on recent analyses of the phase III KEYNOTE-756 and CheckMate 7FL trials, which of the following subgroups of patients with high-risk estrogen receptor (ER)‒positive/HER2-negative early breast cancer (EBC) is most likely derive the highest benefit from the addition of an immune checkpoint inhibitor (ICI) to neoadjuvant chemotherapy and adjuvant endocrine therapy?

The phase III HER2CLIMB-02 trial is comparing tucatinib plus trastuzumab emtansine (T-DM1) vs placebo plus T-DM1 in patients with HER2-positive metastatic breast cancer (MBC) after prior trastuzumab and a taxane, including those with active brain metastases. Which of the following accurately reflects progression-free survival (PFS) and safety outcomes with tucatinib plus T-DM1 from the analysis presented at SABCS 2023?

When counseling older patients with hormone receptor–positive/HER2-negative MBC eligible for sacituzumab govitecan, how would you best describe results from the post hoc subgroup analysis of the phase III TROPiCS-02 trial evaluating the efficacy and safety of sacituzumab govitecan in patients aged 65 years and older vs younger than 65 years in this setting?

Based on the recent analysis of the phase III TROPION-Breast01 trial comparing datopotamab deruxtecan (Dato-DXd) vs chemotherapy, which of the following subgroups of patients with ER-positive/HER2-negative advanced breast cancer (ABC) would be most likely to have a PFS benefit from Dato-DXd?